| Ytd | 44.40% | |
| 1y | -10.31% |
| Open | 4.00 | Prev Close | 4.00 | Low | 4.00 | High | 4.00 | Mkt Cap | 258.25M |
| Vol | 1.46M | Avg Vol | 2.26M | EPS | -1.68 | P/E | -2.38 | Forward P/E | -1.86 |
| Beta | 1.54 | Short Ratio | 7.59 | Inst. Own | 98.53% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | N/A | 50-d Avg | 2.85 | 200-d Avg | 2.79 | 1yr Est | 19.56 |
INZY News
BioMarin's revenue growth is strong, with Q2 2025 revenues up 16% year-over-year and full-year guida
SAN RAFAEL, Calif. , July 1, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) said t
BOSTON, June 20, 2025 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) today announced that i
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr.,
NEW YORK , May 16, 2025 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), ha
NEW YORK , May 16, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigat
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether t
MILWAUKEE--(BUSINESS WIRE)--The Ademi Firm is investigating Inozyme (Nasdaq: INZY) for possible brea
Acquisition is Strong Strategic Fit for BioMarin, Adding INZ-701, a Phase 3 Enzyme Replacement Thera
- Interim data from ENERGY 3 trial highlight INZ-701's potential to modify disease course in ENPP1 D
- Data from the largest retrospective analysis of ENPP1 Deficiency provides insights into the evolut
BOSTON, March 31, 2025 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “In
- Cash, cash equivalents and short-term investments as of December 31, 2024, and anticipated cost sa
BOSTON, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Ino
BOSTON, Feb. 21, 2025 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Ino
BOSTON, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Ino
Inozyme Pharma (INZY) is technically in oversold territory now, so the heavy selling pressure might
BOSTON, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Ino
- Interim data from ENERGY 1, a Phase 1b trial of INZ-701 in infants with ENPP1 Deficiency, on track
- INZ-701 was well-tolerated and significantly increased plasma pyrophosphate (PPi) levels in patien
Gainers TravelCenters of America Inc. (NASDAQ: TA) shares jumped 70.5% to $84.32 after BP announc
Gainers Vaxcyte, Inc. (NASDAQ: PCVX) shares jumped 65% to $33.96 after the company announced pos
Wednesday's session saw 361 companies set new 52-week lows.
On Thursday, 1076 companies hit new 52-week lows.
On Thursday, 529 companies set new 52-week lows.
On Wednesday, 73 stocks hit new 52-week lows.
During Tuesday's session, 454 stocks hit new 52-week lows.
Tuesday's session saw 729 companies set new 52-week lows.